RELB and prostate cancer: The NF‐κB2/p52/RelB pathway represents a major alternative route of NF‐κB signaling (Taniguchi & Karin, 2018), which has been involved in drug resistance in myeloma (Landowski et al, 2003) and prostate cancer (Nadiminty et al, 2013).